CMPS
COMPASS Pathways plc (NASDAQ)
Healthcare — Medical Care Facilities
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Price History
Fundamentals
| Market Cap | $1.79B |
| P/E Ratio (TTM) | - |
| Forward P/E | -12.58 |
| EPS (TTM) | $-3.14 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -68.48% |
| Debt/Equity | 16.32 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $22.33 |
| Analysts | 15 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 65.8 |
| Beta | 2.51 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.40 |
| 52-Week Low | $3.24 |
| 50-Day Avg | $11.25 |
| 200-Day Avg | $7.54 |
| Avg Volume | $4.41M |
| Volume | $4.74M |
Performance Analysis
BULLISHCMPS shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report